Xeris Biopharma Holdings, Inc. Common Stock (XERS)

Price$6.18

Value ScoreD

Growth ScoreB

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-21.85%

Price vs S&P 500 (4W)-5.35%

VGM Score59.56

Market Capitalization$1.02B

P/E Ratio (Annual)1835.49x

All Metrics

P/CF (Annual)35.52x

Book Value / Share (Quarterly)$0.08

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)38.35%

Cash Flow / Share (Quarterly)$0.28

Price vs S&P 500 (YTD)-29.43%

Gross Margin (TTM)85.89%

Net Profit Margin (TTM)3.81%

EPS (TTM)$0.06

10-Day Avg Trading Volume1.43M

EPS Excl Extra (TTM)$0.06

Revenue Growth (5Y)70.26%

EPS (Annual)$0.00

ROI (Annual)0.24%

Gross Margin (Annual)85.41%

Net Profit Margin (5Y Avg)-79.62%

Cash / Share (Quarterly)$0.65

P/E Basic Excl Extra (TTM)84.68x

Revenue Growth QoQ (YoY)38.27%

P/E Normalized (Annual)1835.49x

ROA (Last FY)0.14%

Revenue Growth TTM (YoY)41.47%

EBITD / Share (TTM)$0.26

ROE (5Y Avg)-295.22%

Operating Margin (TTM)11.40%

Cash Flow / Share (Annual)$0.17

P/B Ratio78.15x

P/B Ratio (Quarterly)76.87x

Net Income / Employee (Annual)$1,300

EV / Revenue (TTM)3.58x

Net Interest Coverage (TTM)1.02x

ROA (TTM)3.24%

EV / EBITDA (TTM)24.10x

EPS Incl Extra (Annual)$0.00

Current Ratio (Annual)2.19x

Quick Ratio (Quarterly)1.42x

3-Month Avg Trading Volume1.75M

52-Week Price Return38.56%

EV / Free Cash Flow (Annual)40.33x

P/E Incl Extra (TTM)84.68x

Revenue / Employee (TTM)$723,800

Tangible BV / Share (Quarterly)$-0.95

P/S Ratio (Annual)3.48x

Asset Turnover (Annual)0.76x

52-Week High$10.08

Operating Margin (5Y Avg)-69.12%

EPS Excl Extra (Annual)$0.00

CapEx CAGR (5Y)12.87%

26-Week Price Return-13.93%

Quick Ratio (Annual)1.48x

13-Week Price Return2.32%

Total Debt / Equity (Annual)16.10x

Current Ratio (Quarterly)2.12x

Enterprise Value$1.13B

Revenue / Share Growth (5Y)28.68%

Asset Turnover (TTM)0.85x

Book Value / Share Growth (5Y)-53.08%

Revenue / Employee (Annual)$670,900

Inventory Turnover (Annual)0.73x

Pretax Margin (Annual)0.19%

Cash / Share (Annual)$0.67

3-Month Return Std Dev44.33%

Gross Margin (5Y Avg)80.49%

Net Income / Employee (TTM)$27,600

ROE (Last FY)4.05%

Net Interest Coverage (Annual)1.50x

EPS Basic Excl Extra (Annual)$0.00

P/FCF (TTM)21.36x

Receivables Turnover (TTM)6.14x

EV / Free Cash Flow (TTM)23.70x

Total Debt / Equity (Quarterly)17.00x

EPS Incl Extra (TTM)$0.06

Receivables Turnover (Annual)6.38x

ROI (TTM)5.69%

P/S Ratio (TTM)3.23x

Pretax Margin (5Y Avg)-80.25%

Revenue / Share (Annual)$1.69

Tangible BV / Share (Annual)$-0.72

Forward P/E30.46x

Price vs S&P 500 (52W)14.20%

P/E Ratio (TTM)84.68x

Year-to-Date Return-21.27%

5-Day Price Return1.81%

EPS Normalized (Annual)$0.00

ROA (5Y Avg)-20.79%

Net Profit Margin (Annual)0.19%

Month-to-Date Return0.32%

Cash Flow / Share (TTM)$-0.36

EBITD / Share (Annual)$0.21

Operating Margin (Annual)8.53%

LT Debt / Equity (Annual)16.10x

P/CF (TTM)20.95x

ROI (5Y Avg)-71.13%

P/E Excl Extra (TTM)84.68x

LT Debt / Equity (Quarterly)17.00x

EPS Basic Excl Extra (TTM)$0.06

P/B Ratio (Annual)97.76x

Inventory Turnover (TTM)0.70x

Pretax Margin (TTM)3.81%

Book Value / Share (Annual)$0.08

Price vs S&P 500 (13W)-5.94%

Beta0.78x

P/FCF (Annual)36.41x

Revenue / Share (TTM)$1.77

ROE (TTM)99.74%

52-Week Low$4.30

vGradeD

gGradeB

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.01est. -0.01

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.23

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
XERSXeris Biopharma Holdings, Inc. Common Stock	D	B	B	$6.18
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Xeris Biopharma is a commercial-stage biopharmaceutical company specializing in treatments for chronic endocrine and neurological diseases. The company markets three FDA-approved therapies: Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis. Its Phase 3-ready pipeline includes XP-8121, a once-weekly subcutaneous levothyroxine injection leveraging the company's proprietary XeriSol technology.